Imagine the brain as an intricate puzzle, constantly changing and evolving. In a new study, researchers investigated the impact of hs-CRP concentration on brain structure alterations and cognitive trajectory in Alzheimer’s disease (AD). By analyzing data from over 400 patients with subjective cognitive decline, mild cognitive impairment, and AD, they discovered a fascinating connection. The results showed that higher levels of hs-CRP, a marker of inflammation, were associated with increased gray matter volume in specific regions of the brain, like the left fusiform and parahippocampal gyrus. This finding suggests that hs-CRP may have a protective effect on brain structure in individuals with cognitive decline. Furthermore, the study revealed that lower baseline levels of hs-CRP were linked to greater future cognitive decline in patients with AD. These findings shed light on potential avenues for interventions targeting inflammation to mitigate the progression of AD. To learn more about this exciting research and its implications for understanding Alzheimer’s disease, explore the full article!
IntroductionPresent study was to investigate hs-CRP concentration, brain structural alterations, and cognitive function in the context of AD [Subjective cognitive decline (SCD), mild cognitive impairment (MCI), and AD].MethodsWe retrospectively included 313 patients (Mean age = 76.40 years, 59 SCD, 101 MCI, 153 AD) in a cross-sectional analysis and 91 patients (Mean age = 75.83 years, 12 SCD, 43 MCI, 36 AD) in a longitudinal analysis. Multivariable linear regression was conducted to investigate the relationship between hs-CRP concentration and brain structural alterations, and cognitive function, respectively.ResultsHs-CRP was positively associated with gray matter volume in the left fusiform (β = 0.16, pFDR = 0.023) and the left parahippocampal gyrus (β = 0.16, pFDR = 0.029). Post hoc analysis revealed that these associations were mainly driven by patients with MCI and AD. The interaction of diagnosis and CRP was significantly associated with annual cognitive changes (β = 0.43, p = 0.008). Among these patients with AD, lower baseline CRP was correlated with greater future cognitive decline (r = −0.41, p = 0.013).ConclusionOur study suggests that increased hs-CRP level may exert protective effect on brain structure alterations and future cognitive changes among patients already with cognitive impairment.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.